Dissection of signal transduction pathways as a tool for the development of targeted therapies of hepatocellular carcinoma

Reviews on Recent Clinical Trials

Volumn 2, Issue 3, 2007, Pages 217-236

  Calvisi, Diego F ^a   Pascale, Rosa M ^a   Feo, Francesco ^a  

^a UNIVERSITY OF SASSARI   (Italy)

Author keywords

Apoptosis; Cell cycle; Gene therapy; Genomic instability; Hepatocellular carcinoma; Signal transduction pathways

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; ABT 100; ADENOVIRUS VECTOR; AMINOGUANIDINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; BUTYRIC ACID; CETUXIMAB; ERLOTINIB; ETODOLAC; GEFITINIB; HISTONE DEACETYLASE INHIBITOR; HYALURONIC ACID; LAPATINIB; LENALIDOMIDE; MENATETRENONE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NVP AEW 541; PELITINIB; QUINAZOLINE DERIVATIVE; RAPAMYCIN; SMALL INTERFERING RNA; SORAFENIB; SUNITINIB; THALIDOMIDE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB;

ANTISENSE THERAPY; APOPTOSIS; CANCER GENE THERAPY; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE REGULATION; DNA METHYLATION; DOWN REGULATION; DRUG TARGETING; GENE OVEREXPRESSION; GENE SILENCING; GENETIC SUSCEPTIBILITY; GENOMIC INSTABILITY; HETEROZYGOSITY LOSS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER METASTASIS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; UPREGULATION; VIRAL GENE THERAPY;

ANIMALS; CARCINOMA, HEPATOCELLULAR; DISEASE MODELS, ANIMAL; DNA METHYLATION; GENE SILENCING; GENE THERAPY; GENES, TUMOR SUPPRESSOR; GENOMIC INSTABILITY; HUMANS; LIVER NEOPLASMS; PRECANCEROUS CONDITIONS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 35248880645     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488707781662715     Document Type: Review

References (240)

1. Feitelson MA, Sun B, Satiroglu Tufan NL, Liu J, Pan J, Lian Z. Genetic mechanisms of hepatocarcinogenesis. Oncogene 2000; 221: 2593-604.
2. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5-S16.
3. Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell 2004; 5: 215-9.
4. Feo F, Pascale RM, Simile MM, De Migho MR, Muroni MR, Calvisi DF. Genetic alterations in liver carcinogenesis. Curr Rev Oncog 2000; 11: 19-62.
5. Farber E, Sarma DSR, Hepatocarcinogenesis: A dynamic cellular perspective. Lab Invest 1987; 56: 4-22.
6. Farazi PA, De Pinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev 2006; 6: 674-87.
7. Lee J-S, Chu IS, Mikaelyan A, et al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 2004; 36: 1306-11.
8. Lee JS, Heo J, Libbrecht L, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006; 12: 410-6.
9. Pitot HC, Dragan YP. Stage of tumor progression, progressor agents, and human risk. Proc Soc Exp Biol Med 1993; 202: 37-43.
10. Bannasch P, Nehrbass D, Kopp-Schneider A. Significance of hepatic pre-neoplasia for cancer chemoprevention. In: Miller AB, Bartsch H, Boffetta P, Dragsted L, Vainio H, eds. Biomarkers in Cancer Chemoprevention. Lyon, IARC, 2001: 223-40.
11. Enomoto K, Farber E. Kinetics of phenotypic maturation of remodeling of hyperplastic nodules during liver carcinogenesis. Cancer Res 1982; 42: 2330-5.
12. Bursch W, Taper HS, Lauer B, Schulte-Hermann R. Quantitative histogical and histochemical studies on the occurrence and stages of controlled cell death (apoptosis) during regression of rat liver hyperplasia. Wirchow Arch B Cell Pathol 1985; 50: 153-66.
13. Garcea RL, Daino RM, Pascale RM. et al. Inhibition of promotion and persistent nodule growth by S-adenosyl-L-methionine in rat liver carcinogenesis: Role of remodeling and apoptosis. Cancer Res 1989; 49: 1850-6.
14. Garcea R, Daino L, Pascale RM, et al. Protooncogene methylation and expression in regenerating liver and preneoplastic liver nodules induced in the rat by diethylnitrosamine: effect of variations of S-adenosylmethionine: S-adenosylhomocysteine ratio. Carcinogenesis 1989; 10: 1183-92.
15. INK4A activity in rat liver carcinogenesis and human liver cancer. Hepatology 2005; 42: 1310-9.
16. Feo F, De Miglio MR, Simile MM, et al. Hepatocellular carcinoma as a complex polygenic disease. interpretive analysis of recent developments on genetic predisposition, BBA Cancer Rev 2006; 176: 126-47.
17. Hemminki K, Li X, Familial risks of cancer as a guide to gene identificafion and mode of inheritance. Int J Cancer 2004; 110: 291-4.
18. Johnson SJ, Burr AW, Toole K, Dack CL, Mathew J, Burt AD. Macrophage and hepatic stellate cell responses during experimental hepatocarcinogenesis. J Gastroenterol Hepatol 1998; 13: 145-51.
19. Schiffer E, Housset C, Cacheux W, et al. Expression of heparinbinding epidermal growth factor in human hepatocellular carcinoma. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 2005; 41: 307-14.
20. Marshall C. How do small GTPase signal transduction pathways regulate cell cycle entry? Curr Opin Cell Biol 1999; 11: 732-6.
21. Pascale RM, Simile MM, De Miglio MR, et al. Inhibition of 3-hydroxy-3-methyl glutaryl-CoA reductase activity and gene expression by dehydroepiandrosterone in preneoplastic liver nodules. Carcinogenesis 1995; 16: 1537-42.
22. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001; 410: b37-40.
23. Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 1996; 271: 20608-16.
24. Bulavin DV, Kovalsky O, Hollander MC, Fornace AJ Jr. Loss of oncogenic H-ras-induced cell cycle arrest and p38 mitogen-activated protein kinase activation by disruption of Gadd45a. Mol Cell Biol 2003; 23:3859-71.
25. Hui L, Bakiri L, Mairhorfer A, et al. p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet 2007; 39: 741-9.
26. Woodgett JR. Recent advances in the protein kinase B signaling pathway. Curr Opin Cell Biol 2005; 17: 150-7.
27. Alexis, C, Fourmatgeat P, Delautier D, Groyer A. Insulin-hke growth factor-I stimulates H4II rat hepatoma cell proliferation: dominant role of PI-3'K/Akt signaling. Exp Cell Res 2006; 312: 1142-52.
28. Parekh P, Rao KV. Overexpression of cyclin D1 is associated with elevated levels of MAP kinases, Akt and Pak1 during diethylnitrosamine-induced progressive liver carcinogenesis. Cell Biol Int 2007; 31: 35-43.
29. Ramljak D, Calvert RJ, Wiesenfeld PW, et al. A potential mechanism for furmonisin B(1)-mediated hepatocarcinogenesis: cyclin D1 stabilization associated with activation of Akt and inhibition of GSK-3beta activity. Carcinogenesis 2000; 21: 1537-46.
30. Factor V, Oliver AL, Pants, GR, Thorgeirsson SS, Sonenshein GE, Arsura M. Roles of Akt/PKB and IKK complex in constitutive induction of NF-kB in hepatocellular carcinomas of transforming growth factor alpha/c-myc transgenic mice. Hepatology 2001; 34: 32-41.
31. Datta J, Majumder S, Kutay H, et al. Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein alpha by phosphatidylinositol 3-kinase signaling cascade. Cancer Res 2007; 67: 2736-46.
32. Simile MM, Pagnan G, Pastorino F, et al. Chemopreventive N-(4-hydroxyphenyl) retinamide (fenretinide) targets deregulated NF-kB and Mat1A genes in the early stages of rat liver carcinogenesis. Carcinogenesis 2005; 26: 417-27.
33. Kawanishi S, Hitaku Y, Pinlaor S, Ma N. Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis. Biol Chem 2006; 387: 365-72.
34. Arsura, M, Cavin LG. Nulear factor-kB and liver carcinogenesis. Cancer Lett 2005; 229: 157-69.
35. Kimura H, Esumi H. Reciprocal regulation between nitric oxide and vascular endothelial growth factor in angiogenesis. Acta Biochim Polonica 2003; 50; 49-59.
36. Beck KF, Eberhardt W, Frank S, et al. Inducible NO synthase: role in cellular signalling. J Exp Biol 1999; 202: 45-53.
37. Ahn B, Han BS, Kim DJ, Ohshima H. Immunohistochemical localization of inducible nitric oxide synthase and 3-nitrotyrosine in rat liver tumors induced by N-nitrosodiethylamine. Carcinogenesis 1999; 20: 1337-44.
38. Rahman MA, Dhar DK, Yamaguchi E, et. al. Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases. Clin Cancer Res 2001; 7: 1325-32.
39. Ikeguchi M, Ueta T, Yamane Y, Hirooka Y, Kaibara N. Inducible nitric oxide synthase and survivin messenger RNA expression in hepatocellular carcinoma. Clin Cancer Res 2002; 8: 3131-6.
40. Calvisi DF, Pinna F, Meloni F, et al. DUSP1 Inactivation is Related to Rat Genetic Susceptibility to Hepatocarcinogenesis and Influences Human HCC Prognosis. 2007, submitted.
41. Martínez-Chantar MML, García-Trevijano ER, Latasa MU, et al. Importance of a deficiency in S-adenosyl-L-methionine synthesis on the pathogenesis of liver injury. Am J Clin Nutr 2002; 76: 1177S-82S.
42. García-Trevijano ER, Martínez-Chantar ML, Latasa MU, Mato JM, Avila MA. NO sensitizes rat hepatocytes to proliferation by modifying S-adenosylmethionine levels. Gastroenterology 2002; 122: 1355-63.
43. Majano PL, Garcia-Monzon C, García-Trevijano ER, et al. S-adenosylmethionine modulates inducible nitric oxide synthase gene expression in rat liver and isolated hepatocytes. J Hepatol 2001; 35: 692-9.
44. Calo V, Migliavacca M, Bazan V, et al. STAT proteins: from normal control of cellular events tumorigenesis. J Cell Physiol 2003; 197: 157-68.
45. Sanchez A, Nagy P, Thorgeirsson SS. STAT-3 activity in chemically-induced hepatocellular carcinoma. Eur J Cancer 2003; 39: 2093-8.
46. Ogata H, Chinen T, Yoshida T, et al. Loss of SOCS3 in liver promotes fibrosis by enhancing STAT3-mediated TGF-β1 production. Oncogene 2006; 25: 2520-30.
47. Niwa Y, Kanda H, Shikauchi Y, et al. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signaling in human hepatocellular carcinoma. Oncogene 2005; 24: 6406-17
48. Romach EH, Goldsworthy TL, Maronpot RR, Fox TR. Altered gene expression in spontaneous hepatocellular carcinomas from male B6C3F1 mice. Mol Carcinogen 1997; 19: 31-8.
49. Pascale RM, Simile MM, De Miglio MR, et al. Cell cycle deregulation in liver lesions of rats with and without genetic predisposition to hepatocarcinogenesis. Hepatology 2002; 35: 1341-50.
50. Suchy BK, Sarafoff M, Kerler R, Rabes HM. Amplification, rearrangements, and enhanced expression of c-myc in chemically induced rat liver tumors in vivo and in vitro. Cancer Res 1989; 49: 6781-7.
51. Dang, CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999; 19: 1-11.
52. Wang Z, Wang M, Carr BI. Hepatocyte growth factor enhances protein phosphatase Cdc25A inhibitor compound 5-induced hepatoma cell growth inhibition via Akt-mediated MAPK pathway. J Cell Physiol 2005; 203: 510-9.
53. Pascale RM, Simile MM, Gaspa L, et al. Alterations of ornithine decarboxylase gene during the progression of rat liver carcinogenesis. Carcinogenesis 1993; 14:1077-80.
54. Auvinen M, Paasinen A, Andersson LC, Hölttä E. Ornithine decarboxylase activity is critical for cell transformation. Nature 1992; 360: 355-8.
55. Hibshoosh H, Johnson M, Weinstein IB. Effects of overexpression of ornithine decarboxylase (ODC) on growth control and oncogene-induced cell transformation. Oncogene 1991; 6: 739-43.
56. Santoni-Rugiu E, Jensen MR, Thorgeirsson SS. Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha. Cancer Res 1998; 58: 123-34.
57. Stepanova L, Leng X, Parker SB, Harper JW. Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev 1996; 10: 1491-502.
58. Gaubatz S, Lees JA, Lindeman GJ, Livingston DM. E2F4 is exported from the nucleus in a CRM1-dependent manner. Mol Cell Biol 2001; 21: 1384-92.
59. Stepanova L, Finegold M, DeMayo F, Schmidt EV, Harper JW. The oncoprotein kinase chaperone CDC37 functions as an oncogene in mice and collaborates with both c-myc and cyclin D1 in transformation of multiple tissues. Mol Cell Biol 2000; 20: 4462-73.
60. Cobrinik D. Pocket proteins and cell cycle control. Oncogene 2005; 24: 2796-809.
61. Martens U, Lennartsson P, Hogberg J, Stenius U. Low expression of WAF1/ CIP1/CIP1 gene product, p21, in enzyme-altered foci induced in rat liver by diethylnitrosamine or phenobarbital. Cancer Lett 1996; 104: 21-6.
62. De Miglio MR, Simile MM, Muroni MR, et al. c-myc overexpression and amplification correlate with progression of preneoplastic liver lesions to malignancy in the poorly susceptible Wistar rat strain. Mol Carcinogen 1999; 25: 21-9.
63. Park do Y, Lee CH, Sol MY, Suh KS, Yoon SY, Kim JW. Expression and localization of the Transforming growth factor-β type I receptor and Smads in preneoplastic lesions during chemical hepatocarcinogenesis in rats. J Korean Med Sci 2003; 18: 510-9.
64. Murakami H, Sanderson ND, Nagy P, Marino PA, Merlino G, Thorgeirsson SS. Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis. Cancer Res 1993; 53: 1719-23.
65. Calvisi D, Thorgeirsson SS. Molecular mechanisms of hepatocarcinogenesis in transgenic mouse models of liver cancer. Toxicol Pathol 2005; 33: 181-4.
66. Santoni-Rugiu E, Jensen MR, Factor VM, Thorgeirsson SS. Acceleration of c-myc-induced hepatocarcinogenesis by Co-expression of transforming growth factor (TGF)-alpha in transgenic mice is associated with TGF-betal signaling disruption. Am J Pathol 1999; 154: 1693-700.
67. Calvisi DF, Factor VM, Ladu S, Conner EA, Thorgeirsson SS. Disruption of beta-Catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice. Gastroenterology 2004; 126: 1374-86.
68. Sargent L, Dragan Y, Sattler G, Xu YH, Wiley J, Pitot HC. Specific chromosomal changes in albumin simian virus 40 T antigen transgenic rat liver neoplasms. Cancer Res 1997; 57: 3451-56.
69. Sargent L, Zhou X, Keck CL, et al. Nonrandom cytogenetic alterations in hepatocellular carcinoma from transgenic mice overexpressing c-Myc and transforming growth factor-alpha in the liver. Am J Pathol 1999; 154: 1047-55.
70. Teerguarden JG, Newton MA, Dragan Y. Pitot HC. Genome-wide loss of heterozygosity analysis of chemically induced rat hepatocellular carcinomas reveals elevated frequency of allefic imbalances on chromosomes 1, 6, 8, 11. 17, and 20. Mol Carcinog 2000; 28: 51-61.
71. De Miglio MR, Muroni MR, Simile MM, et al. Frequent loss of heterozygosity at the Hcrl (Hepatocarcinogenesis resistance) locus on chromosome 10 in primary hepatocellular carcinomas from LFF21 rat strain. Hepatology 2001 33: 1110-7.
72. De Miglio MR, Canzian F, Pascale RM, et al. Identification of genetic loci controlling hepatocarcinogenesis on rat chromosomes 7 and 10. Cancer Res 1999; 59: 4651-7.
73. Gariboldi M, Pascale RM, Manenti G, et al. Analysis of loss of heterozygosity in neoplastic nodules induced by diethylnitrosamine in the resistant BFF1 rat strain, Carcinogenesis 1999; 23: 1933-6.
74. Miyasaka K, Ohtake K, Nomura K, et al. Frequent loss of heterozygosity on Chromosome 4 in diethynitrosamine-induced C3H/MSM mouse hepatocellular carcinomas in culture. Mol Carcinog 1995; 13: 37-43.
75. Ogawa K, Osanai M, Obata M, Ishizaki K, Kamiya K. Gain of chromosomes 15 and 19 is frequent in both mouse hepatocellular carcinoma cell lines and primary tumors, but loss of chromosomes 4 and 12 is detected only in the cell lines. Carcinogenesis 1999; 20: 2083-8.
76. Lin YW, Sheu JC, Huang GT, et al. Chromosomal abnormality in hepatocellular carcinoma by comparative genomic hybridisation in Taiwan. Eur J Cancer 1999; 35: 652-8.
77. Piao Z, Kim H, Jeon BK, Lee WJ and Park C. Relationship between loss of heterozygosity of tumor suppressor genes and histologic differentiation in hepatocellular carcinoma. Cancer 1997; 80: 865-72.
78. Haddad R, Held WA. Genomic imprinting and Igf2 influence liver tumorigenesis and loss of heterozygosity in SV40 T antigen transgenic mice. Cancer Res 1997; 57: 4615-23.
79. Pascale RM, De Miglio MR, Muroni MR, et al. c-myc amplification in pre-malignant and malignant lesions induced in rat liver by the resistant hepatocyte model. Int J Cancer 1996; 68: 136-42.
80. Pascale RM, Simile MM, Feo F. Genomic abnormalities in hepatocarcinogenesis. Implications for a chemopreventive strategy. Anticancer Res 1993; 13: 1341-56.
81. Lee HC, Kim M, Wands JR. Wnt/Frizzled signaling in hepatocellular carcinoma. Front Biosci 2006; 11: 1901-15.
82. Gregorieff A, Clevers H. Wnt signaling in the intestinal epithelium: from endoderm to cancer. Genes Dev 2005; 19: 877-90.
83. Tsujiuchi T, Tsutsumi M, Sasaki Y, Takahama M, Konishi Y. Different frequencies and patterns of β-Catenin mutations in hepatocellular carcinomas induced by N-nitrosodiethylamine and a choline-deficient L-aminoacid-defined diet. Cancer Res 1999; 59: 3904-7.
84. Merle P, de la Monte S, Kim M, et al. Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology 2004; 127: 1110-22.
85. Matsumura T, Makino R, Mitamura K. Frequent down-regulation of E-cadherin by genetic and epigenetic changes in the malignant progression of hepatocellular carcinomas. Clin Cancer Res 2001; 7: 594-9.
86. Pang R, Yuen J, Yuen MF, et al. PIN1 overexpression and betacatenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. Oncogene 2004; 23: 4182-6.
87. Tokusashi Y, Fukuda I, Ogawa K. Absence of p53 mutations and various frequencies of Ki-ras exon 1 mutations in rat hepatic tumors induced by different carcinogens. Mol Carcinogen 1994; 10: 45-51.
88. Hulla E, Chen ZY, Eaton DL. Aflatoxin B1-induced rat hyperplastic nodules do not exhibit a site-specific mutation within the p53 gene. Cancer Res 1993; 53: 9-11.
89. Calvert R. Tashiro Y, Buzard G, Diwan B, Weghorst C. Lack of p53 point mutations in chemically induced mouse hepatoblastomas: An end-stage, highly malignant hepatocellular carcinoma. Cancer Lett 1995; 95: 175-80.
90. Sipowicz M, Weghorst C, Shiao Y, et al. Lack of p53 and ras mutations in Helicobacter hepaticus induced liver tumors in A/JCr mice. Carcinogenesis 1997: 18: 233-6.
91. Gomez-Angelats M, Teeguarden JG, Dragan YP, Pitot HC. Mutational analysis of three tumor suppressor genes in two models of rat hepatocarcinogenesis. Mol Carcinogen 1999; 25: 157-63.
92. Tsujiuchi T, Sasaki Y, Kubozoe T, Tsutsumi M, Konishi Y, Nakae D. Alterations of the Fhit gene in hepatocellular carcinomas induced by N-nitrosodiethylamine in rats. Mol Carcinogen 2002; 34: 19-24.
93. Hers I, Wherlock M, Homma Y, Yagisawa H, Tavare JM. Identification of p122RhoGAP (deleted in liver cancer-1) serine-322 as a substrate for protein kinase B and RSK in insulin-stimulated cells. J Biol Chem 2006; 281: 4762-70.
94. Kuo MT, Liu Z, Wei Y, et al. Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-κB signaling. Oncogene 2002; 21: 1945-54.
95. Ghoshal AK. New insight into the biochemical pathology of liver in choline deficiency. Crit Rev Biochem Mol Biol 1995; 30: 263-73.
96. Wainfan E, Poirier LA. Methyl groups in carcinogenesis: effects on DNA methylation and gene expression. Cancer Res 1992; 52: 2071s-7s.
97. Rushmore TH, Ghazarian DM, Subrahmanyan V, Farber E, Ghoshal AK. Probable free radical effects on rat liver nuclei during early hepatocarcinogenesis with a choline-devoid low methionine diet. Cancer Res 1987; 47: 6731-40.
98. Denda A, Kitayama W, Kishida H, et al. Expression of inducible nitric oxide (NO) synthase but not prevention by its gene ablation of hepatocarcinogenesis with fibrosis caused by a choline-deficient, L-amino acid-defined diet in rats and mice. Nitric Oxide 2007; 16: 164-76.
99. James SJ, Pogribny IP, Pogribna M, Miller BJ, Jernigan S, Melnyk S. Mechanisms of DNA damage, DNA hypomethylation, and tumor progression in folate/methyl-deficient rat model of hepatocarcinogenesis. J Nutr 2003; 133: 3740S-7S.
100. Goodhardt, M., Cavelier P., N. Doyen, S. Kallenbach, C. Babinet, and F. Rougeon: Methylation status of immunoglobulin κ gene segments correlates with their recombination potential. Eur J Immunol 1993; 23: 1789-95.
101. Shen, J-C, Rideout WM III, Jones PA. The rate of hydrolytic deamination of 5-methylcytosine in double-stranded DNA. Nucleic Acids Res 1994; 22: 972-6.
102. Denissenko, MF, Chen JX, Tang M-S, Pfeifer GP. Cytosine methylation determines hot spots of DNA damage in the human p53 gene. Proc Natl Acad Sci USA 1997; 94: 3893-8.
103. Kim, Y-I, Pogribny IP, Basnakian AG, et al. Folate deficiency in rats induces DNA strand breaks and hypomethylation within the p53 tumor suppressor gene. Am J Clin Nutr 1997; 65: 46-52.
104. Zingg J-M, Jones PA. Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. Carcinogenesis 1997; 18: 869-82.
105. Schmid, M, Grunert D, Haaf T, Engel W. A direct demonstration of somatically paired heterochromatin of human chromosomes. Cytogenet Cell Genet 1993; 36: 554-61.
106. Kokalj-Vokac N, Almeida A, Viegas-Pequignot E, Jeanpierre M, Malfoy B, Dutrillaux B. Specific induction of uncoiling and recombination by azacytidine in classical satellite-containing constitutive heterochromatin. Cytogenet Cell Genet 1993; 63: 11-5.
107. Ji W, Hernandez R, Zhang XY, et al. DNA demethylation and pericentromeric rearrangements of chromosome 1. Mutat Res 1997; 379: 33-41.
108. Hsieh LL, Wainfan E, Hoshina S, Dizik M, Weinstein IB. Altered expression of retrovirus-like sequences and cellular oncogenes in mice fed methyl-deficient diets. Cancer Res 1989; 49: 3795-9.
109. Masuhara M, Katyl SL, Nakamura T, Shinozuka H. Differential expression of hepatocyte growth factor, transforming growth factor-alpha and transforming growth factor-beta 1 messenger RNAs in two experimental models of liver cell proliferation. Hepatology 1992; 16: 1241-9.
110. Albright CD, Zeisel SH. Choline deficiency causes increased localization of transforming growth factor-beta1 signaling proteins and apoptosis in the rat liver. Pathobiology 1997; 65: 264-70.
111. Tsujiuchi T, Sasaki Y, Oka Y, Konishi Y, Tsutsumi M. Fhit gene alterations in hepatocarcinogenesis induced by a choline-deficient L-amino acid-defined diet in rats. Mol Carcinog. 2003; 36: 147-52.
112. Smith ML, Yeleswarapu L, Scalamogna, P, Locker J, Lombardi B. p53 mutations in hepatocellular carcinomas induced by a choline-devoid diet in male Fischer 344 rats. Carcinogenesis 1993; 14: 503-10.
113. Tsujiuchi T, Kido A, Nakae D, et al. Infrequent Ki-ras and an absence of p53 mutations in hepatocellular carcinomas induced by a choline deficient L-amino acid defined diet in rats. Cancer Lett 1996; 108: 137-41.
114. Sasaki Y, Tsujiuchi T, Murata N, Kubozoe T, Tsutsumi M, Konishi Y. Absence of p16, p21 and p53 gene alterations in hepatocellular carcinomas induced by N-nitrosodiethylamine or a choline-deficient L-amino acid-defined diet in rats. Cancer Lett 2000; 152: 71-7.
115. Powell CL, Kosyk O, Bradford BU, et al. Temporal correlation of pathology and DNA damage with gene expression in a choline-deficient model of rat liver injury. Hepatology 2005; 42: 1137-47.
116. Calvisi DF, Simile MM, Ladu S, et al. Role of perturbation of methionine metabolism and global DNA methylation in the generation of genomic instability in transgenic mouse models of liver cancer. Int J Cancer 2007, in press.
117. Robertson KD. DNA methylation and human disease. Nat Rev Genet 2005; 6: 597-610.
118. De Smet C, Lurquin C, Lethe B, Martelange V, Boon T. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 1999; 19: 7327-35.
119. Nakamura N, Takenaga K. Hypomethylation of the metastasis-associated S100A4 gene correlates with gene activation in human colon adenocarcinoma cell lines. Clin Exp Metastasis 1998; 16: 471-9.
120. Mato JM, Corrales FJ, Lu SC, Avila MA. S-Adenosylmethionine: a control switch that regulates liver function. FASEB J 2002; 16: 15-26.
121. Cai J, Sun WM, Hwang JJ, Stain SC, Lu SC. Changes in S-adenosylmethionine synthetase in human liver cancer: molecular characterization and significance. Hepatology 1996; 24: 1090-7.
122. Cai J, Mao Z, Hwang JJ, Lu SC. Differential expression of methionine adenosyltransferase genes influences the rate of growth of human hepatocellular carcinoma cells. Cancer Res 1998; 58: 1444-50.
123. Martinez-Chantar ML, Corrales FJ, Martinez-Cruz LA, et al. Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A. FASEB J 2002; 16: 1292-4.
124. Pascale RM, Marras V, Simile MM, et al. Chemoprevention of rat liver carcinogenesis by S-adenosyl-L-methionine: A long-term study. Cancer Res 1992; 52: 4979-86.
125. Pascale RM, Simile MM, De Miglio MR, et al. Chemoprevention by S-adenosyl-L-methionine of rat liver carcinogenesis initiated by 1,2-dimethylhydrazine and promoted by orotic acid. Carcinogenesis 1995, 16: 427-30.
126. Pascale R, Simile MM, Ruggiu ME, et al. Reversal by 5-azacytidine of the S-adenosyl-L-methionine induced inhibition of the development of putative preneoplastic foci in rat liver carcinogenesis. Cancer Lett 1991; 56: 259-65.
127. Duong FH, Christen V, Filipowicz M, Heim MH. S-Adenosyl-methionine and betaine correct hepatitis C virus induced inhibition of interferon signaling in vitro. Hepatology 2006; 43: 796-806.
128. Mato JM, Camara J, Fernandez de Paz J, et al. S-adenosyl-methionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999; 30: 1081-9.
129. Lieber CS. S-adenosyl-L-methionine: its role in the treatment of liver disorder. Am J Clin Nutr 2002; 76: 1183S-7S.
130. Roncaglia N, Locatelli A, Arreghini A, et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis. BJOG 2004; 111: 17-21.
131. Mischoulon D, Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr 2002; 76: 1158S-61S.
132. Tchantchou F, Graves M, Ortiz D, Rogers E, Shea TB. Dietary supplementation with 3-deaza-adenosine, N-acetyl cysteine, and S-adenosyl methionine provide neuroprotection against multiple consequences of vitamin deficiency and oxidative challenge: relevance to age-related neurodegeneration. Neuromolecular Med 2004; 6: 93-103.
133. Jhaveri MS, Wagner C, Trepel JB. Impact of extracellular folate levels on global gene expression. Mol Pharmacol 2001; 60: 1288-95
134. Singh SM, Murphy B, O'Reilly RL. Involvement of gene-diet/drug interaction in DNA methylation and its contribution to complex diseases: from cancer to schizophrenia. Clin Genet 2003; 64: 451-60.
135. Sohn KJ, Stempak JM, Reid S, Shirwadkar S, Mason JB, Kim YI. The effect of dietary folate on genomic and p53-specific DNA methylation in rat colon. Carcinogenesis 2003; 24: 81-90.
136. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002; 21: 5427-40.
137. Momparler RL. Cancer epigenetics. Oncogene2003; 22: 6479-83.
138. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61: 3225-9.
139. Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004; 10: 1871-4.
140. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 2000; 60: 6039-44.
141. Widschwendter M, Siegmund KD, Muller HM, et al. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 2004; 64: 3807-13.
142. Aparicio A, Weber JS. Review of the clinical experience with 5-azacytidine and 5-aza-2-deoxycytidine in solid tumors. Curr Opin Investig Drugs 2002; 3: 627-33.
143. Rodriguez J, Frigola J, Vendrell E, et al. Chromosomal Instability Correlates with Genome-wide DNA Demethylation in Human Primary Colorectal Cancers. Cancer Res 2006; 66: 8462-8.
144. Gaudet F, Hodgson JG, Eden A, et al. Induction of tumors in mice by genomic hypomethylation. Science (Wash DC) 2003; 300: 489-92.
145. Itano O, Ueda M, Kikuchi K, et al. Correlation of postoperative recurrence in hepatocellular carcinoma with demethylation of repetitive sequences. Oncogene 2002; 21: 789-97.
146. Calvisi DF, Ladu S, Gorden A, et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006; 130: 1117-29.
147. Nakanishi K, Sakamoto M, Yamasaki S, Todo S, Hirohashi S. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer 2005; 103: 307-12.
148. Rahman MA, Dhar DK, Yamaguchi E, et al. Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases. Clin Cancer Res 2001; 7: 1325-32.
149. Tannapfel A, Wittekind C. Genes involved in hepatocellular carcinoma: deregulation in call cycling and apoptosis. Virchows Arch 2002; 440: 345-52.
150. Greenbaum LE. Cell cycle regulation and hepatocarcinogenesis. Cancer Biol Ther 2004; 3: 1200-7.
151. Buendia MA. Genetics of hepatocellular carcinoma. Semin Cancer Biol 2000; 10: 185-200.
152. Coleman WB. Mechanisms of human hepatocarcinogenesis. Curr Mol Med 2003; 3: 573-88.
153. Inui Y, Higashiyama S, Kawata S, et al. Expression of heparin-binding epidermal growth factor in human hepatocellular carcinoma. Gastroenterology 1994; 107: 1799-804.
154. Chung YH, Kim JA, Song BC, et al. Expression of transforming growth factor-alpha mRNA in livers of patients with chronic viral hepatitis and hepatocellular carcinoma. Cancer 2000; 89: 977-82.
155. Desbois-Mouthon C, Cacheux W, Blivet-Van Eggelpoel MJ, et al. Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. Int J Cancer 2006; m 199: 2557-66.
156. Berasain C, Castillo J, Perugorria MJ, Prieto J, Avila MA. Amphiregulin: A new growth factor in hepatocarcinogenesis. Cancer Lett 2007; [Epub ahead of print]
157. Ding X, Yang LY, Huang GW, Wang W, Lu WQ. ADAM17 mRNA expression and pathological features of hepatocellular carcinoma. World J Gastroenterol 2004; 10: 2735-9.
158. Amaravadi R, Thompson CB. The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 2005; 115: 2618-24.
159. Lee JW, Soung YH, Kim SY, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005; 24: 1477-80.
160. Tanaka Y, Kanai F, Tada M, et al. Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients. Oncogene 2006; 25: 2950-2.
161. Adjei AA, Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol 2005; 23: 5386-403.
162. Laurent-Puig P, Legoix P, Bluteau O, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001; 120: 1763-1773.
163. Hsu HC, Jeng YM, Mao TL, Chu JS, Lai PL, Peng SY. Beta-Catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol 2000; 157: 763-70.
164. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92: 725-34.
165. Lozano G, Zambetti GP. Gankyrin: an intriguing name for a novel regulator of p53 and RB. Cancer Cell 2005; 8: 3-4.
166. Tangkijvanich P, Anukulkarnkusol N, Suwangool P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on alpha-fetoprotein levels. J Clin Gatroenterol 2000; 31: 301-8.
167. Xu X, Yamamoto H, Sakon M, et al. Overexpression of CDC25A phosphatase is associated with hypergrowth activity and poor prognosis of human hepatocellular carcinomas. Clin Cancer Res 2003; 9: 1764-72.
168. Helène C. Control of oncogene expression by antisense nucleic acids. Eur J Cancer 1994; 30A: 1721-6.
169. Weiss B, Davidkova G, Zhou LW. Antisense RNA gene therapy for studying and modulating biological processes. Cell Mol Life Sci 1999; 55: 334-58.
170. Tang G. siRNA and miRNA: an insight into RISCs. Trends Biochem Sci 2005; 30: 106-14.
171. Lu PY, Xie F, Woodle MC. In vivo application of RNA interference: from functional genomics to therapeutics. Adv Genet 2005; 54: 117-42.
172. Simile MM, De Miglio MR, Muroni MR, et al. Down-regulation of c-myc and Cyclin D1 genes by antisense oligodeoxy nucleotides inhibits the expression of E2F1 and in vitro growth of HepG2 and Morris 5123 liver cancer cells. Carcinogenesis 2004; 25: 333-41.
173. Li K, Lin SY, Brunicardi FC, Seu P. Use of RNA interference to target cyclin E-overexpressing hepatocellular carcinoma. Cancer Res 2003; 63:
174. Hung L, Kumar V. Specific inhibition of gene expression and transactivation functions of hepatitis B virus X protein and c-myc by small interfering RNAs. FEBS Lett 2004; 560: 210-4.
175. Liu W, Nakamura H, Yamamoto T, et al. Vitamin K2 inhibits the proliferation of HepG2 cells by up-regulating the transcription of p21 gene. Hepatol Res 2007; 37: 360-5.
176. Zhu BH, Yao ZX, Luo SJ, et al. Effects of antisense oligonucleotides of PKC-alpha on proliferation and apoptosis of HepG2 in vitro. Hepatobiliary Pancreat Dis Int 2005; 4: 75-9.
177. Wu TT, Hsieh YH, Hsieh YS, Liu JY. Reduction of PKC-alpha decreases cell proliferation, migration, and invasion of human malignant hepatocellular carcinoma. J Cell Biochem 2007; [Epub ahead of print].
178. Sangkhathat S, Kusafuka T, Miao J, et al. In vitro RNA interference against beta-catenin inhibits the proliferation of pediatric hepatic tumors. Int J Oncol 2006; 28: 715-22.
179. Kuntzen C, Sonuc N, De Toni EN, et al. Inhibition of c-Jun-N-terminal-kinase sensitizes tumor cells to CD95-induced apoptosis and induces G2/M cell cycle arrest. Cancer Res 2005; 65: 6780-8.
180. Wirth T, Kuhnel F, Fleischmann-Mundt B, et al. Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1. Cancer Res 2005; 65(16): 7393-402.
181. Yamaguchi Y, Shiraki K, Fuke H, et al. Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand-and chemotherapeutic agent-induced cell death. Oncol Rep 2005; 14: 1311-6.
182. Kanda T, Yokosuka O, Imazeki F, Arai M, Saisho H. Enhanced sensitivity of human hepatoma cells to 5-fluorouracil by small interfering RNA targeting Bcl-2. DNA Cell Biol 2005; 24: 805-9.
183. Li H, Fu X, Chen Y, et al. Use of adenovirus-delivered siRNA to target oncoprotein p28GANK in hepatocellular carcinoma. Gastroenterology 2005; 128: 2029-41.
184. Hori T, Kato S, Saeki M, et al. cDNA cloning and functional analysis of p28 (Nas6p) and p40.5 (Nas7p), two novel regulatory subunits of the 26S proteasome. Gene 1998; 216: 113-22.
185. Li J, Tsai MD. Novel insights into the INK4-CDK4/6-Rb pathway: counter action of gankyrin against INK4 proteins regulates the CDK4-mediated phosphorylation of Rb. Biochemistry 2002; 41: 3977-83.
186. Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature 2001; 411: 349-54.
187. Li X, Deng W, Lobo-Ruppert SM, Ruppert JM. Gli1 acts through Snail and E-cadherin to promote nuclear signaling by beta-catenin. Oncogene 2007; 26: 4489-98.
188. Kim Y, Yoon JW, Xiao X, Dean NM, Monia BP, Marcusson EG. Selective down-regulation of glioma-associated oncogene 2 inhibits the proliferation of hepatocellular carcinoma cells. Cancer Res 2007; 67: 3583-93.
189. Liu YJ, Wang Q, Li W, Huang XH, et al. Rab23 is a potential biological target for treating hepatocellular carcinoma. World J Gastroenterol 2007; 13: 1010-7.
190. Lu X, Qin W, Li J, et al. The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6L of proton pump. Cancer Res 2005; 65: 6843-9.
191. Salvi A, Arici B, De Petro G, Barlati S. Small interfering RNA urokinase silencing inhibits invasion and migration of human hepatocellular carcinoma cells. Mol Cancer Ther 2004; 3: 671-8.
192. Salvi A, Arici B, Alghisi A, Barlati S, De Petro G. RNA interference against urokinase in hepatocellular carcinoma xenografts in nude mice. Tumour Biol 2007; 28: 16-26.
193. Djojosubroto MW, Choi YS, Lee HW, Rudolph KL. Telomeres and telomerase in aging, regeneration and cancer. Mol Cells. 2003; 15: 164-75. Erratum in: Mol Cells 2003; 16: 142.
194. Plentz RR, Park YN, Lechel A, et al. Telomere shortening and inactivation of cell cycle checkpoints characterize human hepatocarcinogenesis. Hepatology 2007; 45: 968-76.
195. M'kacher R, Bennaceur-Griscelli A, Girinsky T, et al. Telomere shortening and associated chromosomal instability in peripheral blood lymphocytes of patients with Hodgkin's lymphoma prior to any treatment are predictive of second cancers. Int J Radiat Oncol Biol Phys 2007; 68: 465-71.
196. Lechel A, Holstege H, Begus Y, et al. Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease. Gastroenterology 2007; 132: 1465-75.
197. Djojosubroto MW, Chin AC, Go N, et al. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Hepatology 2005; 42: 1127-36.
198. Xu GW, Sun ZT, Forrester K, Wang XW, Coursen J, Harris CC. Tissue-specific growth suppression and chemosensitivity promotion in human hepatocellular carcinoma cells by retroviral-mediated transfer of the wild-type p53 gene. Hepatology 1996; 24: 1264-8.
199. Mitry RR, Sarraf CE, Havlik R, Habib NA. Detection of adenovirus and initiation of apoptosis in hepatocellular carcinoma cells after Ad-p53 treatment. Hepatology 2000; 31: 885-9.
200. Choi JY, Park YM, Byun BH, et al. Adenovirus-mediated p53 tumor suppressor gene therapy against subcutaneous HuH7 hepatoma cell line nodule of nude mice. J Korean Med Sci 1999; 14: 271-6.
201. Sandig V, Brand K, Herwig S, Lukas J, Bartek J, Strauss M. Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat Med 1997; 3: 313-9.
202. Anderson SC, Johnson DE, Harris MP, et al. p53 gene therapy in a rat model of hepatocellular carcinoma: intra-arterial delivery of a recombinant adenovirus. Clin Cancer Res 1998; 4: 1649-59.
203. Kuriyama S, Masui K, Kikukawa M, et al. Complete cure of established murine hepatocellular carcinoma is achievable by repeated injections of retroviruses carrying the herpes simplex virus thymidine kinase gene. Gene Ther 1999; 6: 525-33.
204. Yamanaka T, Shiraki K, Sugimoto K, et al. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology 2000; 32: 482-90.
205. Ganten TM, Koschny R, Haas TL, et al. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 2005; 42: 588-97.
206. Koschny R, Ganten TM, Sykora J, et al. TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology 2007; 45: 649-58.
207. Miyashita K, Shiraki K, Fuke H, et al. The cyclin-dependent kinase inhibitor flavopiridol sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis. Int J Mol Med 2006; 18: 249-56.
208. Liu Y, Poon RT, Shao, W, et al. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma. Cancer Lett 2007; 248: 32-40.
209. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66: 11851-8.
210. Zacharoulis D, Hatzitheofilou C, Athanasiou E, Zacharoulis S. Antiangiogenic strategies in hepatocellular carcinoma: current status. Expert Rev Anticancer Ther 2005; 5: 645-56.
211. Carloni V, Vizzutti F, Pantaleo P. Farnesyltransferase inhibitor, ABT-100, is a potent liver cancer chemopreventive agent. Clin Cancer Res 2005; 11: 4266-74.
212. Nakanishi K, Sakamoto M, Yasuda J, et al. Critical involvement of the phosphatidylinositol 3-kinase/Akt pathway in anchorage-independent growth and hematogeneous intrahepatic metastasis of liver cancer. Cancer Res 2002; 62: 2971-5.
213. Amaravadi R, Thompson CB. The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 2005; 115: 2618-24.
214. Adjei AA, Hidalgo M. Treating cancer by blocking cell signals. J Clin Oncol 2005; 23: 5279-80.
215. Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004; 10: 8421-5.
216. Ozaki I, Zhang H, Mizuta T, et al. Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D1 expression through inhibition of nuclear factor kappaB; activation. Clin Cancer Res 2007; 13: 2236-45.
217. Kuba K, Matsumoto K, Date K, Shimura H, Tanaka M, Nakamura T. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 2000; 60(23): 6737-43.
218. Heideman DA, Overmeer RK van Beusechem et al. Inhibition of angiogenesis and HGF-cMET-elicited malignant processes in human hepatocellular carcinoma cells using adenoviral vector-mediated NK4 gene therapy. Cancer Gene Ther 2005; 12: 954-62.
219. Gao G, Li Y, Gee S, et al. Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor: a possible mechanism for the anti-angiogenic activity of plasminogen kringle 5. J Biol Chem 2002; 277: 9492-7.
220. Matsumoto K, Ishikawa H, Nishimura D, et al. Antiangiogenic property of pigment epithelium-derived factor in hepatocellular carcinoma. Hepatology 2004; 40: 252-9.
221. Liu Y, Poon RT, Li Q, Kok TW, Lau C, Fan ST. Both antiangiogenesis-and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 2005; 65: 3691-9.
222. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 2000; 37: 431-502.
223. Kinoshita T, Takahashi Y, Sakashita T, Inoue H, Tanabe T, Yoshimoto T. Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenases 1 and 2 in human colon carcinoma cells. Biochim Biophys Acta 1999; 1438: 120-30.
224. Hu K-Q. Rationale and feasibility of chemoprovention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors. J Lab Clin Med 2002; 139: 234-43.
225. Sawaoka H, Tsuji S, Tsujii M, et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest 1999; 79: 1469-77.
226. Cheng J, Imanishi H, Liu W, et al. Involvement of cell cycle regulatory proteins and MAP kinase signaling pathway in growth inhibition and cell cycle arrest by a selective cyclooxygenase.2 inhibitor, etodolac, in human hepatocellular carcinoma cell lines. Cancer Sci 2004; 95: 666-73.
227. Coradini D, Zorzet S, Rossin R, et al. Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But. Clin Cancer Res 2004; 10: 4822-30.
228. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol. 2005; 23: 2445-59. Erratum in: J Clin Oncol 2005; 23: 6281.
229. Camp ER, Summy J, Bauer TW, Liu W, Gallick GE, Ellis LM. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 2005; 11: 397-405.
230. Huether A, Hopfner M, Sutter AP, Schuppan D, Scherubl H. Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J Hepatol 2005; 43: 661-9.
231. Huether A, Hopfner M, Sutter AP, Baradari V, Schuppan D, Scherubl H. Signaling pathways involved in the inhibition of epidermal growth factor receptor by erlotinib in hepatocellular cancer. World J Gastroenterol 2006; 12: 5160-7.
232. Schiffer E, Housset C, Cacheux W, et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 2005; 41: 307-14.
233. Hopfner M, Huether A, Sutter AP, Baradari V, Schuppan D, Scherubl H. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Biochem Pharmacol 2006; 71: 1435-48. E
234. Hwang LH. Gene therapy strategies for hepatocellular carcinoma. J Biomed Sci 2006; 13: 453-68.
235. Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene 2006; 25: 3866-84.
236. Epstein RJ, Leung TW. Reversing hepatocellular carcinoma progression by using networked biological therapies. Clin Cancer Res 2007; 13: 11-17.
237. Mancheno-Corvo P, Martin-Duque P. Viral gene therapy. Clin Transl Oncol 2006; 8: 858-67.
238. Breckpot K, Aerts JL, Thielemans K. Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Ther 2007; 14: 847-62.
239. Schepelmann S, Springer CJ. Viral vectors for gene-directed enzyme prodrug therapy. Curr Gene Ther 2006; 6: 647-70.
240. Thorne SH. Strategies to achieve systemic delivery of therapeutic cells asnd microbes to tumors. Expert Opin Biol Ther 2007; 7: 41-51.